Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Medis Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (1052)
ARTG (149)
Cancellation or suspension (26)
Listed medicine compliance report (5)
Prescription medicine registration (2)

Date

2024 (866)
2023 (3)
2022 (29)
2021 (106)
2020 (31)
2019 (6)
2018 (6)
2017 (47)
2016 (5)
2015 (29)
2014 (29)
2013 (29)
2012 (23)
2011 (12)
2010 (3)
2009 (8)
2008 (1)
1993 (1)

Results for "[search-keyword]"

Search

Sponsor content

1234 result(s) found, displaying 281 to 290

ROSUVASTATIN-GA rosuvastatin (as calcium) 40mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ROSUVASTATIN-GA rosuvastatin (as calcium) 40mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
CANDESARTAN-GA candesartan cilexetil 32 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
CANDESARTAN ACTAVIS candesartan cilexetil 8 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
CANDESARTAN ACTAVIS candesartan cilexetil 16 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
CANDESARTAN-GA candesartan cilexetil 8 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
CANDESARTAN ACTAVIS candesartan cilexetil 4 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
CANDESARTAN ACTAVIS candesartan cilexetil 32 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
CANDESARTAN ACTAVIS candesartan cilexetil 4 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
PIVAINE 0.5% (w/v) ropivacaine hydrochloride (as monohydrate) 100 mg/20 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

18 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd

Pages

First page
Previous page
…
Page 25
Page 26
Page 27
Page 28
Current page 29
Page 30
Page 31
Page 32
Page 33
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.